Inhibitory effects of fucoidan on NMDA receptors and l-type Ca2+ channels regulating the Ca2+ responses in rat neurons

Pharm Biol. 2019 Dec;57(1):1-7. doi: 10.1080/13880209.2018.1548626.

Abstract

Context: Fucoidan, a sulphated polysaccharide extracted from brown algae [Fucus vesiculosus Linn. (Fucaceae)], has multiple biological activities.

Objective: The effects of fucoidan on Ca2+ responses of rat neurons and its probable mechanisms with focus on glutamate receptors were examined.

Materials and methods: The neurons isolated from the cortex and hippocampi of Wistar rats in postnatal day 1 were employed. The intracellular Ca2+ responses triggered by various stimuli were measured in vitro by Fura-2/AM. Fucoidan at 0.5 mg/mL or 1.5 mg/mL was applied for 3 min to determine its effects on Ca2+ responses. RT-PCR was used to determine the mRNA expression of neuron receptors treated with fucoidan at 0.5 mg/mL for 3 h.

Results: The Ca2+ responses induced by NMDA were 100% suppressed by fucoidan, and those induced by Bay K8644 90% in the cortical neurons. However, fucoidan has no significant effect on the Ca2+ responses of cortical neurons induced by AMPA or quisqualate. Meanwhile, the Ca2+ responses of hippocampal neurons induced by glutamate, ACPD or adrenaline, showed only a slight decrease following fucoidan treatment. RT-PCR assays of cortical and hippocampal neurons showed that fucoidan treatment significantly decreased the mRNA expression of NMDA-NR1 receptor and the primer pair for l-type Ca2+ channels, PR1/PR2.

Discussion and conclusions: Our data indicate that fucoidan suppresses the intracellular Ca2+ responses by selectively inhibiting NMDA receptors in cortical neurons and l-type Ca2+ channels in hippocampal neurons. A wide spectrum of fucoidan binding to cell membrane may be useful for designing a general purpose drug in future.

Keywords: Ca transient; Cortical and hippocampal neuron; mRNA expression of PR1/PR2; sulphated polysaccharide.

MeSH terms

  • 3-Pyridinecarboxylic acid, 1,4-dihydro-2,6-dimethyl-5-nitro-4-(2-(trifluoromethyl)phenyl)-, Methyl ester / pharmacology
  • Animals
  • Calcium / metabolism*
  • Calcium Channels, L-Type / metabolism*
  • Cells, Cultured
  • Cerebellar Cortex / cytology
  • Cerebellar Cortex / drug effects
  • Excitatory Amino Acid Agonists / pharmacology
  • Glutamic Acid / pharmacology
  • Hippocampus / cytology
  • Hippocampus / drug effects
  • N-Methylaspartate / pharmacology
  • Neurons / drug effects*
  • Neurons / metabolism
  • Polysaccharides / pharmacology*
  • Rats
  • Rats, Wistar
  • Receptors, AMPA / metabolism
  • Receptors, Glutamate / metabolism
  • Receptors, N-Methyl-D-Aspartate / antagonists & inhibitors*
  • Receptors, N-Methyl-D-Aspartate / biosynthesis
  • Receptors, N-Methyl-D-Aspartate / metabolism

Substances

  • Calcium Channels, L-Type
  • Excitatory Amino Acid Agonists
  • NR1 NMDA receptor
  • Polysaccharides
  • Receptors, AMPA
  • Receptors, Glutamate
  • Receptors, N-Methyl-D-Aspartate
  • Glutamic Acid
  • N-Methylaspartate
  • 3-Pyridinecarboxylic acid, 1,4-dihydro-2,6-dimethyl-5-nitro-4-(2-(trifluoromethyl)phenyl)-, Methyl ester
  • fucoidan
  • Calcium

Grants and funding

The present work was mainly supported by the grant “Medical Photonics,” the 21st century Center of Excellence (COE: No. F13) from the Ministry of Education, Culture, Sports, Science and Technology, Japan and Collaborative Innovation Center of Henan University of Traditional Chinese Medicine, China.